Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age.
Journal article
Bijukchhe SM. et al, (2024), Vaccine
Intravenous immunoglobulin treatment in childhood encephalitis (IgNiTE): a randomised controlled trial.
Journal article
Hill M. et al, (2023), BMJ Open, 13
Direct inference and control of genetic population structure from RNA sequencing data.
Journal article
Fachrul M. et al, (2023), Commun Biol, 6
Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) - a protocol for two parallel, open-label, randomised controlled trials.
Journal article
Kelly S. et al, (2023), Trials, 24
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
Journal article
Liu X. et al, (2023), J Infect, 87, 18 - 26
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
Journal article
Kelly E. et al, (2023), J Infect
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Journal article
Shaw RH. et al, (2023), J Infect, 86, 574 - 583
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
Journal article
Liu X. et al, (2023), J Infect, 86, 540 - 541
Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh.
Journal article
Khanam F. et al, (2023), Vaccine
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Journal article
Voysey M. et al, (2023), Clin Exp Immunol, 211, 280 - 287
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Journal article
Fidler S. et al, (2023), Clin Infect Dis, 76, 201 - 209
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Journal article
Shaw RH. et al, (2022), Lancet Respir Med, 10, 1049 - 1060
Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study.
Journal article
Shrestha S. et al, (2022), Lancet Glob Health, 10, e1494 - e1504
Successful integration of newborn genetic testing into UK routine screening using prospective consent to determine eligibility for clinical trials.
Journal article
Bendor-Samuel OM. et al, (2022), Arch Dis Child
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Journal article
Li G. et al, (2022), Lancet, 399, 2212 - 2225
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Journal article
Munro APS. et al, (2022), Lancet Infect Dis
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
Journal article
Ogbe A. et al, (2022), JCI Insight, 7
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Journal article
Stuart ASV. et al, (2022), Lancet, 399, 36 - 49